00:25:10 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-29 Kvartalsrapport 2024-Q3
2024-08-30 Kvartalsrapport 2024-Q2
2024-05-31 Kvartalsrapport 2024-Q1
2024-05-29 X-dag ordinarie utdelning POLAR 0.00 SEK
2024-05-28 Årsstämma
2024-02-23 Bokslutskommuniké 2023
2023-11-24 Kvartalsrapport 2023-Q3
2023-09-08 Extra Bolagsstämma 2023
2023-08-25 Kvartalsrapport 2023-Q2
2023-05-26 Kvartalsrapport 2023-Q1
2023-05-17 Årsstämma
2023-05-05 X-dag ordinarie utdelning POLAR 0.00 SEK
2023-03-13 Extra Bolagsstämma 2022
2023-02-24 Bokslutskommuniké 2022
2022-11-25 Kvartalsrapport 2022-Q3
2022-08-26 Kvartalsrapport 2022-Q2
2022-05-27 Kvartalsrapport 2022-Q1
2022-05-06 X-dag ordinarie utdelning POLAR 0.00 SEK
2022-05-05 Årsstämma
2022-02-25 Bokslutskommuniké 2021
2021-11-26 Kvartalsrapport 2021-Q3
2021-08-27 Kvartalsrapport 2021-Q2
2021-05-28 Kvartalsrapport 2021-Q1
2021-05-06 X-dag ordinarie utdelning POLAR 0.00 SEK
2021-05-05 Årsstämma
2021-02-26 Bokslutskommuniké 2020
2020-11-27 Kvartalsrapport 2020-Q3
2020-08-28 Kvartalsrapport 2020-Q2
2020-07-01 X-dag ordinarie utdelning POLAR 0.00 SEK
2020-06-30 Årsstämma
2020-05-29 Kvartalsrapport 2020-Q1
2020-02-28 Bokslutskommuniké 2019
2020-02-14 Extra Bolagsstämma 2020
2019-10-23 Kvartalsrapport 2019-Q3
2019-07-24 Kvartalsrapport 2019-Q2
2019-05-07 Split POLAR 16:1
2019-04-26 Kvartalsrapport 2019-Q1
2019-03-19 Årsstämma
2019-02-04 X-dag ordinarie utdelning POLAR 0.00 SEK
2019-02-01 Bokslutskommuniké 2018

Beskrivning

LandSverige
ListaSpotlight
SektorHälsovård
IndustriMedicinteknik
Polarcool är verksamt inom medicinteknik. Idag är bolaget inriktade mot att produkter och lösningar inriktade för skador inom sport och aktivitet. Störst fokus återfinns inom forskning och utveckling av produkter som används vid behandling av hjärnskador vid exempelvis boxning, rugby och amerikansk fotboll. Verksamhet innehas på global nivå, med störst närvaro inom den europeiska marknaden.
2024-08-12 08:31:00

The medical technology company PolarCool AB (publ.) has signed a distributor agreement with sports technology company eo for the Australian market. The agreement follows the recent TGA market approval for PolarCap® System in Australia.

PolarCool develops the product PolarCap®, which alleviates the effects of concussions. The primary customers are sports clubs and facilities in ice hockey, rugby, football, and handball, but also other sports with an increased risk of concussion.

eo (https://www.eolab.com/) are an Australian sports technology company, focused on enhancing athletic performance through innovative sports science and technology. The company has a broad expertise in sports technology, a deep market knowledge, and extensive network within the Australian sports industry. Additionally, eo's proven track record of successfully launching and scaling sports technology products ensures effective market penetration and growth for PolarCap® System in Australia.

PolarCool CEO Erik Andersson comments:

-We are delighted to announce our partnership with eo as our distributor for the Australian market. Our companies share similar values and missions, making this collaboration a perfect fit. Enabling us to enter the Australian market marks a significant milestone for PolarCool's international expansion and aligns with our short-term goal of becoming profitable.

The Australian sports market has been of particular interest to PolarCool due to the prevalence of contact sports played in the country. For the past 18 months, PolarCool has held a TGA Medical exemption agreement with the rugby league team, Manly Warringah Sea. The exemption has enabled their leading team doctor, Dr. Paul Bloomfield, to provide PolarCap® System to the team, and also to introduce it to other teams in the top Australian National Rugby League (NRL).